BioSpace News Archive

The San Diego center has been conducting research with the innovative brain stimulating technology

RENFLEXIS™ has been added to drug formulary for the treatment of adult and pediatric Crohn’s disease and ulcerative colitis, as well as for the treatment of fistulising Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis in adults.

The startup company will initially focus on infants suffering from neonatal abstinence syndrome.

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today an exclusive distributorship with FlexDex, a groundbreaking medical device company that extends intuitively controlled articulation to laparoscopic instruments.

In an historic decision, the American Osteopathic Association’s House of Delegates amended governing documents to allow their MD counterparts full membership in the organization, which represents the interests of the nation’s more than 137,000 osteopathic physicians (DOs) and osteopathic medical students.

ExThera Medical Corporation, a developer of therapies for removing bacteria and viruses from blood, today announced results from a prospective, non-randomized clinical trial evaluating the safety and performance of the Seraph® 100 Microbind® Affinity Blood Filter (Seraph) in renal replacement therapy patients who developed bacteremia

Over 1,600 entrepreneurs, corporations, development organizations, governments, investors and academic institutions from over 64 countries met at the Singularity University (SU) Global Summit to learn more about the application of rapidly accelerating technology to large-scale global issues.

As digital technologies define and drive a new era in patient care, Columbia Business School Executive Education has teamed up with HITLAB, a digital health innovation organization that focuses on the diffusion of technology to improve lives worldwide, to offer an industry-first program that distills how digital technologies can transform life science research, clinical development, patient experience, operations, and business models.

COMPASS Pathways has received approval from the US Food and Drug Administration (FDA) for a clinical trial in psilocybin therapy for treatment-resistant depression.

In an age of selfies and constant social media sharing, a growing number of teenagers are undergoing plastic surgery to alter their appearance.